Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates